Strategies for ADC bioanalysis
Wednesday 19 March 2025
07:00 [PST], 10:00 [EST], 15:00 [GMT]
During this webinar, a team of experts from ICON will discuss the specifics of bioanalytical methods for antibody-drug conjugates (ADCs).
ADCs form a group of new pharmaceutically active molecules with significant potential benefits for patients. Recent structural advancements have further enhanced their pharmaceutical appeal, leading to increased development efforts by many companies. However, analyzing ADCs presents unique challenges, requiring both ligand binding assays and LC–MS/MS assays. In this webinar, ICON’s experts will explore the complexities of ADC assays in detail.
What will you learn?
- Bioanalytical considerations for selecting the right assays
- Bioanalytical development and validation parameters specific to ADCs
Who this may interest?
-
Bioanalytical scientists and project managers new to ADC bioanalysis
-
Outsourcing managers working with ADCs
-
Clinical staff at pharma or biotech companies interested in learning more about ADC bioanalysis
Chairi Misrielal
Project Manager, Bioanalytical Laboratories
ICON (Assen, Netherlands)
Chairi has a bachelor’s degree in Pharmacy and a master’s degree in Medical Pharmaceutical Drug Innovation. Following a PhD scholarship, she successfully defended her thesis focused on autophagy and multiple sclerosis. In 2022, Chairi joined ICON as a Project Manager, where she utilizes her expertise to lead and support innovative projects within the bioanalytical laboratories.
Kevin Roback
Principal Scientist, Method Development and Validation
ICON (NY, USA)
Kevin is a Principal Scientist in the Method Development and Validation group at ICON Bioanalytical Laboratories. He holds a bachelor’s degree in Mathematics and Neuroscience and began his career at ICON in 2018. Kevin’s initial focus was on sample analysis but he has since shifted to developing and validating ligand binding assays to assess the pharmacokinetics, pharmacodynamics and immunogenicity of large molecule therapeutics and biomarkers.
Mackenzie Bentley
Manager, Bioanalytical Services
ICON (KS, USA)
Mackenzie has a bachelor’s degree in Chemistry and has been working in the bioanalytical space for over 10 years. Her focus has been development, validation and bioanalysis of small and large molecule assays. Mackenzie has worked for ICON plc for 2 years as the Bioanalytical Services Manager over LC–MS, supporting method validation and bioanalysis.
In association with:
